Agendia Appoints Peter W. Schineller as Chief Commercial Officer

       Agendia Appoints Peter W. Schineller as Chief Commercial Officer

Veteran Diagnostics and Biotech Executive to Lead Global Commercialization

PR Newswire

IRVINE, Calif. and AMSTERDAM, June 3, 2013

IRVINE, Calif. and AMSTERDAM, June 3, 2013 /PRNewswire/ -- Agendia, a leader
in molecular cancer diagnostics, today announced the addition of Peter W.
Schineller as its Chief Commercial Officer. In this newly created position,
Mr. Schineller will lead Agendia's global commercialization activities as it
delivers technologies to translate personalized diagnostics into actionable,
patient-centered solutions for clinicians.

Mr. Schineller's 25-year professional career spans both the diagnostic and
pharmaceutical industry. Most recently, Mr. Schineller served as Senior Vice
President and Chief Commercial Officer at Alexza Pharmaceuticals. Prior to
that, he was Senior Vice President and General Manager at Ventana Medical
Systems, a Roche company; and Senior Vice President Sales, Marketing and
Commercial Operations, at Genoptix Medical Laboratories, acquired by

Mr. Schineller was also a co-founder at Verus Pharmaceuticals and held
positions of increasing responsibility in sales and marketing with Abbott
Laboratories, Dura/Elan and Cypress Bioscience. Prior to entering the
healthcare industry, Mr. Schineller served as a Commissioned Officer in the
United States Marine Corps where he attained the rank of Captain.

"As we continue our growth momentum into 2013, we are committed to building
out a world class organization capable of managing and growing a much larger
company. To that end, we are thrilled to add Peter Schineller to our
executive team," said David Macdonald, Agendia's Chief Executive Officer. "Mr.
Schineller's depth of experienced senior leadership of global commercial
organizations will help us perpetuate our volume growth, which exceeded 140
percent in 2012."

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets
FFPE-based genomic diagnostic products, which help support physicians with
their complex treatment decisions. Agendia's breast cancer Symphony™ suite was
developed using unbiased gene selection, analyzing the complete human genome,
ensuring 100% definitive results for cancer patients. Symphony includes
MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence
assay, as well as BluePrint®, a molecular subtyping assay, TargetPrint®, an
ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection
assay. Together, these tests help physicians determine a patient's individual
risk for metastasis, which patients will benefit from chemo, hormonal, or
combination therapy, and which patients do not require these treatments and
can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of
genomic products in development. The Company collaborates with pharmaceutical
companies, leading cancer centers and academic groups to develop companion
diagnostic tests in the area of oncology and is a critical partner in the
ISPY-2 and MINDACT trials. For more information, please visit

Matt Clawson or                Liz Dowling (Medical & Consumer Media)
Len Hall (Financial Media)      Dowling & Dennis Public Relations
Allen & Caron Inc. 949-474-4300 415-388-2794   

SOURCE Agendia

Press spacebar to pause and continue. Press esc to stop.